153 related articles for article (PubMed ID: 34136833)
1. Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.
Vora AA; Mondala PK; Costello C; MacLeod AR; Crews LA
STAR Protoc; 2021 Jun; 2(2):100565. PubMed ID: 34136833
[TBL] [Abstract][Full Text] [Related]
2. IRF4 addiction in multiple myeloma.
Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
[TBL] [Abstract][Full Text] [Related]
3. IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.
Zhang S; Xu J; Wu S; Wang R; Qu X; Yu W; Li J; Chen L
Med Oncol; 2013; 30(2):594. PubMed ID: 23666852
[TBL] [Abstract][Full Text] [Related]
4. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract][Full Text] [Related]
5. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
Agnarelli A; Chevassut T; Mancini EJ
Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
[TBL] [Abstract][Full Text] [Related]
6. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption.
Mondala PK; Vora AA; Zhou T; Lazzari E; Ladel L; Luo X; Kim Y; Costello C; MacLeod AR; Jamieson CHM; Crews LA
Cell Stem Cell; 2021 Apr; 28(4):623-636.e9. PubMed ID: 33476575
[TBL] [Abstract][Full Text] [Related]
7. Circ_0005615 contributes to the progression and Bortezomib resistance of multiple myeloma by sponging miR-185-5p and upregulating IRF4.
Fu C; Wang J; Hu M; Zhou W
Anticancer Drugs; 2022 Oct; 33(9):893-902. PubMed ID: 36136989
[TBL] [Abstract][Full Text] [Related]
8. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
Ohguchi H; Hideshima T; Bhasin MK; Gorgun GT; Santo L; Cea M; Samur MK; Mimura N; Suzuki R; Tai YT; Carrasco RD; Raje N; Richardson PG; Munshi NC; Harigae H; Sanda T; Sakai J; Anderson KC
Nat Commun; 2016 Jan; 7():10258. PubMed ID: 26728187
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
[TBL] [Abstract][Full Text] [Related]
11. IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis.
Low MSY; Brodie EJ; Fedele PL; Liao Y; Grigoriadis G; Strasser A; Kallies A; Willis SN; Tellier J; Shi W; Gabriel S; O'Donnell K; Pitt C; Nutt SL; Tarlinton D
Cell Rep; 2019 Nov; 29(9):2634-2645.e5. PubMed ID: 31775034
[TBL] [Abstract][Full Text] [Related]
12. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
[TBL] [Abstract][Full Text] [Related]
13. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
[TBL] [Abstract][Full Text] [Related]
14. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
15. Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis.
Tang TF; Chan YT; Cheong HC; Cheok YY; Anuar NA; Looi CY; Gan GG; Wong WF
Cell Immunol; 2022 Oct; 380():104594. PubMed ID: 36081178
[TBL] [Abstract][Full Text] [Related]
16. Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-IRF4-MYC Axis.
Murugesan A; Lassalle-Claux G; Hogan L; Vaillancourt E; Selka A; Luiker K; Kim MJ; Touaibia M; Reiman T
J Nat Prod; 2020 Dec; 83(12):3526-3535. PubMed ID: 33210536
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric detection of human telomerase reverse transcriptase (hTERT) expression in a subpopulation of bone marrow cells.
Handa H; Matsushima T; Nishimoto N; Inoue M; Saitoh T; Yokohama A; Tsukamoto N; Mitsui T; Nakahashi H; Toyama K; Karasawa M; Ogawara H; Nojima Y; Murakami H
Leuk Res; 2010 Feb; 34(2):177-83. PubMed ID: 19604579
[TBL] [Abstract][Full Text] [Related]
18. IRF4: Immunity. Malignancy! Therapy?
Shaffer AL; Emre NC; Romesser PB; Staudt LM
Clin Cancer Res; 2009 May; 15(9):2954-61. PubMed ID: 19383829
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Kawano Y; Fujiwara S; Wada N; Izaki M; Yuki H; Okuno Y; Iyama K; Yamasaki H; Sakai A; Mitsuya H; Hata H
Int J Oncol; 2012 Sep; 41(3):876-84. PubMed ID: 22766978
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
